XML 52 R28.htm IDEA: XBRL DOCUMENT v3.22.4
BUSINESS SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
BUSINESS SEGMENT INFORMATION BUSINESS SEGMENT INFORMATION
    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers, consumers, and ACOs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for greater than 95% of net revenues in 2022, 2021 and 2020.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions.
    
    As of December 31, 2022, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States.
    The following table is a summary of segment information for the years ended December 31, 2022, 2021 and 2020. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the segments are the same as those of the Company as set forth in Note 2.
202220212020
Net revenues:  
DIS business$9,609 $10,494 $9,139 
All other operating segments274 294 298 
Total net revenues$9,883 $10,788 $9,437 
Operating earnings (loss):  
DIS business$1,704 $2,646 $2,201 
All other operating segments20 29 39 
General corporate activities(296)(294)(269)
Total operating income1,428 2,381 1,971 
Non-operating (expense) income, net(193)218 (87)
Income before income taxes and equity in earnings of equity method investees1,235 2,599 1,884 
Income tax expense(264)(597)(460)
Equity in earnings of equity method investees, net of taxes44 78 75 
Net income1,015 2,080 1,499 
Less: Net income attributable to noncontrolling interests69 85 68 
Net income attributable to Quest Diagnostics$946 $1,995 $1,431 

    Depreciation and amortization expense for the years ended December 31, 2022, 2021 and 2020 were as follows:
    
202220212020
DIS business$305 $294 $249 
All other operating segments12 10 8 
General corporate120 104 104 
Total depreciation and amortization$437 $408 $361 
    Capital expenditures for the years ended December 31, 2022, 2021 and 2020 were as follows:
202220212020
DIS business$384 $379 $394 
All other operating segments19 14 15 
General corporate1 10 9 
Total capital expenditures$404 $403 $418 

    The approximate percentage of net revenues by major service for the years ended December 31, 2022, 2021 and 2020 was as follows:
202220212020
Routine clinical testing and other services44 %40 %41 %
COVID-19 testing services15 26 29 
Gene-based and esoteric (including advanced diagnostics) testing services32 26 22 
Anatomic pathology testing services6 5 5 
All other3 3 3 
Net revenues100 %100 %100 %